IT Brief Asia - Technology news for CIOs & IT decision-makers
Asia
Arrow Ventures backs Nutrivert's US livestock trials

Arrow Ventures backs Nutrivert's US livestock trials

Tue, 17th Nov 2026 (Today)
Joseph Gabriel Lagonsin
JOSEPH GABRIEL LAGONSIN News Editor

Arrow Ventures has committed up to USD $4.85 million to Nutrivert to support US trials of a non-antibiotic livestock treatment. The funding will back studies involving 4,800 pigs in the US Midwest.

Nutrivert is testing its LDPP product against four comparator groups: pigs receiving LDPP, antibiotics, both treatments, or neither. The studies aim to measure weight gain, feed conversion efficiency and overall mortality under commercial production conditions.

The Singapore-based investor was founded by Australian veterinary pharmaceuticals entrepreneur Nick Bova. It is also seeking up to USD $125 million in direct investment for its venture fund, which focuses on small biotechnology companies developing veterinary medicines.

LDPP is being developed as an immune stimulant for livestock. Nutrivert says it is intended to strengthen resistance to disease, reduce inflammation and support growth, while offering producers an alternative to antibiotics used in animal production.

For decades, antibiotics have been used in livestock production to promote growth and improve feed efficiency, although many countries have restricted their use for this purpose. Reducing unnecessary antibiotic use is also part of broader efforts to limit antimicrobial resistance, which affects the effectiveness of antibiotics used to treat infections in humans.

US trials

The current US studies are a significant step for Nutrivert because they are designed to test whether LDPP can match or improve the feed conversion outcomes associated with antibiotics. Feed conversion measures how much feed is needed to produce a given amount of animal weight gain and is a key cost factor in swine production.

Peter Selover, Chief Financial Officer and Co-Founder of Nutrivert, said the trials were assessing weight gain and feed conversion efficiency.

"Our objective is to demonstrate that LDPP can deliver commercially meaningful improvements in health and feed efficiency without relying on antibiotics. These trials are an important step in establishing its potential as an alternative for livestock producers. If we can show we are just as good as antibiotics and do not need them anymore, that is what everybody wants," Selover said.

He said the two trials were intended to account for differences in animal health and environmental conditions that could affect the results. Selover previously held senior roles including Chief Executive Officer at Exubrion Therapeutics and Head of Corporate Development at Merial, which is now part of Boehringer Ingelheim Animal Health.

According to Selover, Nutrivert has secured patents in multiple markets, but the company still faces the usual development pathway for a veterinary medicine. Further trials and safety assessments will be required before the product can be commercialised, and the company estimates US Food and Drug Administration approval remains about three years away, subject to trial results, safety data and regulatory requirements.

Investment focus

Arrow Ventures has active investments in five animal health biotechnology companies, including Nutrivert. Its other portfolio companies are developing pain relief medicines for cats and dogs, treatments for endocrine disease in horses, and a treatment for dental disease in dogs.

Bova said Arrow Ventures chose Nutrivert because it is developing a non-antibiotic product for a part of animal agriculture where antibiotic use remains significant. Swine accounts for 34% of meat consumed globally, and the sector remains a heavy user of antibiotics.

"Getting livestock to grow in healthier and more efficient ways means they reach market weight faster and with less feed. Feed costs represent the largest operating expense in commercial swine production, so even modest improvements in feed conversion ratio are economically meaningful to producers," said Nick Bova, Founder of Arrow Ventures.

Nutrivert began work on LDPP nearly a decade ago. The product is a synthetic compound designed to mimic a naturally occurring component of bacterial cell walls, without killing bacteria or exerting an antibacterial effect. The compound interacts with NOD2, a receptor involved in the body's immune response, and the company believes modulating that pathway could improve growth and feed efficiency without antibiotics.

Bova said the trials would need to show the product performs consistently across several measures before it can move further through development.

"The opportunity needs to be assessed carefully around target animal performance, safety, residues, manufacturing, regulatory requirements and whether the benefit is repeatable under commercial conditions," Bova said.

Arrow Ventures reviewed nearly 100 other companies over the past year while building its investment pipeline. Bova said the fund was seeking additional capital because specialist investors in animal health remain limited despite a steady supply of early-stage companies.

"We need more funds to capitalise on these opportunities," Bova said.